Mechanisms of secretion and spreading of pathological tau protein.

Brunello CA, Merezhko M, Uronen RL, Huttunen HJ. · 2020

Read Mechanisms of secretion and spreading of pathological tau protein. by Brunello CA, Merezhko M, Uronen RL, Huttunen HJ. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7190606.txt.

Introduction

Brunello and co-authors review how harmful tau protein leaves cells and spreads. Their article appeared in Cellular and Molecular Life Sciences. Tau tangles build up in the brain in Alzheimer's disease and related disorders. These clumps can pass from cell to cell. Each new cell may then form its own clumps. This prion-like spread may drive disease progress. The review focuses on how tau gets out of cells.

The authors describe several release routes for tau. Some tau crosses the cell membrane directly. Other tau leaves inside small vesicles such as exosomes. Cells may shed tau to cut their own toxic load. Tau can also be released in normal cell activity. Neighboring brain cells then take the protein up. The authors weigh what is known and what stays unclear. Readers get a map of a key step in tau disease spread.

Catalog record

CREATORBrunello CA, Merezhko M, Uronen RL, Huttunen HJ.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE123 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7190606

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Mechanisms of secretion and spreading of pathological tau protein By Cecilia A. Brunello, Maria Merezhko, Riikka-Liisa Uronen, Henri J. Huttunen Published in: Cellular and Molecular Life Sciences: CMLS DOI: 10.1007/s00018-019-03349-1 ABSTRACT Accumulation of misfolded and aggregated forms of tau protein in the brain is a neuropathological hallmark of tauopathies, such as Alzheimer’s disease and frontotemporal lobar degeneration. Tau aggregates have the ability to transfer from one cell to another and to induce templated misfolding and aggregation of healthy tau molecules in previously healthy cells, thereby propagating tau pathology across different brain areas in a prion-like manner. The molecular mechanisms involved in cell-to-cell transfer of tau aggregates are diverse, not mutually exclusive and only partially understood. Intracellular accumulation of misfolded tau induces several mechanisms that aim to reduce the cellular burden of aggregated proteins and also promote secretion of tau aggregates. However, tau may also be released from cells physiologically unrelated to protein aggregation. Tau secretion involves multiple vesicular and non-vesicle-mediated pathways, including secretion directly through the plasma membrane. Consequently, extracellular tau can be found in various forms, both as a free protein and in vesicles, such as exosomes and ectosomes. Once in the extracellular space, tau aggregates can be internalized by neighboring cells, both neurons and glial cells, via endocytic, pinocytic and phagocytic mechanisms. Importantly, accumulating evidence suggests that prion-like propagation of misfolding protein pathology could provide a general mechanism for disease progression in tauopathies and other related neurodegenerative diseases. Here, we review the recent literature on cellular mechanisms involved in cell-to-cell transfer of tau, with a particular focus in tau secretion. INTRODUCTION Demographic aging is increasing the prevalence and societal cost of dementia. The number of people living with dementia is expected to reach 130 million people by 2050 (World Alzheimer Report 2015). Most chronic neurodegenerative diseases are characterized by progressive accumulation of protein aggregates in the nervous system. A common neuropathological hallmark in Alzheimer’s disease (AD), the most common type of aging-related dementia, is cerebral accumulation of neurofibrillary tangles (NFT), composed of aggregated tau protein, which appear to spread from one affected brain region to other areas of the brain as the disease progresses. Similar accumulation of tau inclusions in brain is observed in, e.g., frontotemporal dementia (FTD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Pick’s disease (PiD). Slow spreading of pathologically misfolded tau protein may also be a central event in development and progression of chronic traumatic encephalopathy (CTE), which is often associated with repeated head injuries. The cellular mechanisms of spreading of pathological proteins, such as tau, α-synuclein, β-amyloid peptide (Aβ) and TDP-43, have been receiving increasing attention, and better understanding of the spreading mechanisms is expected to accelerate development of disease-modifying therapies for these devastating neurodegenerative diseases. Tau is a microtubule-binding protein enriched in neurons Tau is one of the many microtubule-associated proteins (MAP) that have an important function of regulating microtubules (MT) to ensure proper cytoskeletal organization and trafficking [1], which is particularly important in highly polarized neuronal cells whose functionality and viability depend on transport of cellular cargo to and from axonal and dendritic peripheries [2–4]. Tau has important physiological functions in regulating MT, including MT polymerization, stabilization and suppression of MT dynamics. Dysregulation of the tau–MT complex leads to tau detachment and instability and disassembly of MTs, eventually leading to perturbation of MT-dependent transport and impaired maintenance of cellular polarity and viability [4, 5]. Tau is present in neurons and, to a lesser degree, in glial cells [6, 7]. Tau is mainly an axonal protein in mature neurons, but it can also be found in the nucleus, mitochondria, dendrites, synapses, and at the plasma membrane (PM) [8–13]. This localization pattern suggests that besides the main function of MT regulation, tau may have other roles in cells. Synaptic tau has been reported to be involved in synaptic development of newborn hippocampal neurons [14]. Also, a role for tau in neuronal activity has been proposed, as tau knockout mice display impaired long-term depression in the hippocampus [11]. Tau also interacts with nucleic acids and can localize to the nucleus, and upon binding to DNA it promotes DNA stability [15], suggesting that tau may have a role in DNA protection [16]. Finally, several domains of the tau protein have the ability to interact with lipids and membranes [17], and one of tau kinases, Fyn, is mainly located in PM microdomains called lipid rafts, where tau can also be recruited [18]. It is also possible that tau localized at the PM occupies a role as a signaling regulator, via its interaction with membrane receptors [19, 20]. Tau is encoded by the MAPT gene, which in humans is located on the chromosome 17. Tau is composed of 16 exons which give rise to six different splicing isoforms, which span from 352 to 441 amino acids (aa) [21], depending on alternative splicing of exons 2, 3 and 10 (Fig. 1a). Exons 2 and 3 encode for 29 amino acid repeats, both located at the N-terminal part of the protein, and alternative splicing of exons 2 and 3 or exon 2 alone produces three N-terminal protein variants 0N, 1N (additional 29 aa) or the less abundant 2N (additional 58 aa). Exon 10 encodes for one of the four possible microtubule-binding repeat domains (MTBD), which are 31–32 aa long imperfect repeat sequences, located in the C-terminal half of the tau protein and affecting both microtubule-binding affinity and fibrillization properties of tau. Splicing isoforms of tau contain either three (3R) or four (4R) MTBDs, which affects their microtubule-binding affinity (4R > 3R) and also their propensity for aggregation. The ratio between 3R and 4R isoforms is developmentally regulated as human fetal tau consists mostly the shortest form 0N3R, while in the adult brain all six isoforms coexist. Also, species-specific differences exist, as for example adult mice display exclusively 4R-tau isoforms [22].Fig. 1The structural basis of tau function and aggregation. a The domain structure of human tau protein. Location of the projection domain, proline-rich domain, MTBDs, and the parts of tau protein encoded by the alternatively spliced exons 2, 3 and 10 are shown on top of the longest tau isoform (2N4R, 441 aa). Below the location of key phosphorylated residues, the two hexapeptides, the two cysteines and examples of FTLD-associated mutations in the MTBDs are shown. b Microtubules (blue and green) are formed by the assembly of α- and β-tubulin dimers into protofilaments that associate laterally into hollow tubes. Tau (red) binds to the surface of microtubules interacting with α- and β-tubulin via the MTBDs. The image was prepared based on a cryo-EM structure of microtubule-associated synthetic tau (PDB: 6CVN). c Structure of a paired helical filament (PHF) fragment isolated from AD brain. The filaments are formed of anti-parallel β-sheets, with the protofilament core formed by the four MTBDs of tau. The location of the tau hexapeptide sequence is indicated. Image was prepared based on a cryo-EM structure (PDB: 5O3L) Different functional domains characterize the tau protein (Fig. 1a). The N-terminal projection domain consists of residues 1–150 (of the longest isoform) and it regulates microtubule binding even though it is not directly involved in the physical interaction [23]. Absence of the N-terminus alters cellular localization of tau, promoting cytosol to

Read the complete text